Novo Nordisk, Hims reach deal to end bitter dispute over Wegovy sales

Novo Nordisk dropped its patent infringement lawsuit against Hims & Hers over compounded Wegovy sales. Under the settlement, Hims agreed to stop advertising compounded GLP-1 products and will offer brand-name Wegovy on its platform. However, Hims can continue providing compounded versions when clinically necessary. Novo reserves the right to refile the lawsuit in the future, suggesting the dispute may not be permanently resolved.